Erlotinib

Erlotinib (CP-358774) is a first-generation, ATP-competitive inhibitor targeting EGFR mutants like exon 19 deletions and L858R. It is widely used in preclinical in vitro and in vivo studies of non-small cell lung cancer, though its application can lead to the acquisition of the C797S resistance mutation.

Product Specifications

CAS Number

183321-74-6

Product Name Alternative

R1415, R-1415, R 1415, tumor, cell, CP358774, CP-358774, CP 358774, directly, autophosphorylation, Autophagy, cancer, acting, EGFR, Epidermal growth factor receptor, ErbB-1, Erlotinib, Inhibitor, HER1, intact, inhibit, non-small, NSC718781, NSC-718781, OSI744, OSI-744, OSI774, OSI-774, OSI 744, OSI 774, NSC 718781, lung

Field of Research

Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Purity

98.19% (May vary between batches)

Solubility

10% DMSO+40% PEG300+5% Tween 80+45% Saline:7.2 mg/mL (18.3 mM) ; DMSO:255 mg/mL (648.13 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:12 mg/mL (30.5 mM)